Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : mRNA-based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sinopharm Unit Gets Ok For Clinical Trials Of mRNA Covid Vaccine
Details : Sinopharm's mRNA-based COVID-19 vaccine was developed using the traditional method, by means of an inactivated virus, in this case the coronavirus, which causes COVID-19 - is killed or modified in such a way that it is unable to replicate.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
January 19, 2023
Lead Product(s) : mRNA-based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved
Sponsor : ChromaDex, Inc
Deal Size : Undisclosed
Deal Type : Agreement
Details : Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.
Brand Name : Tru Niagen
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 10, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Sponsor : ChromaDex, Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Brii Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership will accelerate stockpiling, channel distribution and regional access of the amubarvimab/romlusevimab combination. Amubarvimab and Romlusevimab are non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID...
Brand Name : BRII-196
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 30, 2022
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Brii Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Inactivated SARS-CoV-2 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sinopharm's COVID Booster Reverses Antibody Decline, Enhances Cell-Based Responses - Study
Details : BBIBP-CorV vaccine is an inactivated SARS-CoV-2 vaccine (Vero cell), indicated the potential of BBIBP-CorV to provide cross-protection against other SARS-CoV-2 strains.
Brand Name : BBIBP-CorV
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 17, 2021
Lead Product(s) : Inactivated SARS-CoV-2 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Inactivated Covid-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
China Grants Conditional Market Approval for Sinopharm CNBG’S COVID-19 Vaccine
Details : The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, Chinese equivalent of FDA.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
January 02, 2021
Lead Product(s) : Inactivated Covid-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Inactivated Covid-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Beijing Institute of Biological Product
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MOHAP, in collaboration with Department of Health Abu Dhabi, DOH, has reviewed Sinopharm CNBG’s interim analysis of the phase III trials, which shows Beijing Institute of Biological Product’s inactivated vaccine to have 86 percent efficacy against CO...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
December 09, 2020
Lead Product(s) : Inactivated Covid-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Beijing Institute of Biological Product
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Inactivated SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
China's Sinopharm Says Data 'Better Than Expected" From Unit's COVID-19 Vaccine Trials
Details : Sinopharm's Vero cell is under Phase III randomized, double blind trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 Vaccines in healthy population aged 18 years old and above.
Brand Name : Vero cell
Molecule Type : Vaccine
Upfront Cash : Not Applicable
November 11, 2020
Lead Product(s) : Inactivated SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Fosun Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Shanghai Fosun Pharma, Sinopharm Group Sign Deal to Supply BioNTech Coronavirus Vaccine Candidate
Details : Shanghai Fosun Pharmaceutical has signed a strategic cooperation agreement with Sinopharm Group to supply a coronavirus vaccine candidate developed by German firm BioNTech.
Brand Name : BNT162
Molecule Type : Vaccine
Upfront Cash : Undisclosed
September 07, 2020
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Fosun Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Inactivated Covid-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sinopharm Shares Phase 2 Data On Inactivated Covid-19 Vaccine
Details : Sinopharm's inactivated COVID-19 vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy will require phase 3 trials.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
August 13, 2020
Lead Product(s) : Inactivated Covid-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
China's Sinopharm Starts Phase III Trial of COVID-19 Vaccine in Bahrain
Details : Sinopharm has begun Phase III clinical trials of a COVID-19 vaccine in Bahrain, after launching similar trials in the United Arab Emirates last month.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
August 10, 2020
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?